Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

Cancer

Volumn 100, Issue 12, 2004, Pages 2607-2612

  Anagnostopoulos, Athanasios ^a   Aleman, Ana ^a   Ayers, Gregory ^a   Donato, Michele ^a   Champlin, Richard ^a   Weber, Donna ^a   Alexanian, Raymond ^a   Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous stem cell transplantation; High dose melphalan; Multiple myeloma; Preparative regimen

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; THIOTEPA;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; THIOTEPA; TREATMENT OUTCOME;

EID: 2642517876     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20294     Document Type: Article

References (19)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
2. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol. 2001;38: 21-27.
3. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12:759-763.
4. Harousseau J, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 2002;16:245-253.
5. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99: 731-735.
6. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27:1037-1043.
7. Shimoni A, Smith TL, Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001;27:821-828.
8. Alexanian R, Balcerzak S, Bonnet J, et al. Prognostic factors in multiple myeloma. Cancer. 1975;36:1192-1201.
9. Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993;82:2324-2328.
10. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
11. Anderson KC, Kyle RA, Dalton WS, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology (Am Soc Hematol Educ Program). 2000:147-165.
12. Anagnostopoulos A, Aleman A, Yang Y, et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant. 2004;33:623-628.
13. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998;102:495-502.
14. Majolino I, Vignetti M, Meloni G, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica. 1999;84:844-852.
15. Bjorkstrand B, Svensson H, Goldschmidt H, et al. EBMT Registry results of autologous bone marrow and peripheral blood stem cell transplantation [abstract]. Presented at the VII International Multiple Myeloma Workshop, Stockholm, Sweden, September 1-5, 1999.
16. Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol. 2000;109:138-147.
17. Barlogie BM, Shaughnessy J, Sawyer J, et al. Total Therapy II (TTII) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial Total Therapy I (TTI) (N = 231) [abstract]. Blood. 2001;98 Suppl 1:352a.
18. Donato M, Weber D, Alexanian R, et al. High dose topotecan melphalan and cyclophosphamide (TMC): a new regimen for autologous transplantation in multiple myeloma [abstract]. Blood. 2000;96 Suppl 1:798a.
19. 166Ho-DOTMP plus high dose chemotherapy in patients with multiple myeloma [abstract]. Presented at the VIII International Multiple Myeloma Workshop, Banff, Alberta, Canada, May 4-8, 2001.